AR044802A1 - Sales farmaceuticamente aceptables, de derivados de acidos carboxilicos - Google Patents

Sales farmaceuticamente aceptables, de derivados de acidos carboxilicos

Info

Publication number
AR044802A1
AR044802A1 ARP040102112A ARP040102112A AR044802A1 AR 044802 A1 AR044802 A1 AR 044802A1 AR P040102112 A ARP040102112 A AR P040102112A AR P040102112 A ARP040102112 A AR P040102112A AR 044802 A1 AR044802 A1 AR 044802A1
Authority
AR
Argentina
Prior art keywords
pharmaceutically acceptable
acceptable salts
acid derivatives
carboxyl acid
dyslipidemias
Prior art date
Application number
ARP040102112A
Other languages
English (en)
Inventor
Ralf Ragnar
Erica Stahle
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR044802A1 publication Critical patent/AR044802A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/18—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides
    • C07C235/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se refiere a una sal de calcio o magnesio de ácido (2S)-2-etoxi-3-(4-{2[hexil(2-feniletil)amino]-2-oxoetoxi]fenil)propanoico, a procesos para preparar dichos compuestos, utilidad en el tratamiento de afecciones clínicas que incluyen trastornos en los lípidos (dislipidemias) asociados o no a la resistencia a la insulina y otras manifestaciones del síndrome metabólico, a métodos para su uso terapéutico y a composiciones farmacéuticas que las contienen.
ARP040102112A 2003-06-18 2004-06-17 Sales farmaceuticamente aceptables, de derivados de acidos carboxilicos AR044802A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0314136.3A GB0314136D0 (en) 2003-06-18 2003-06-18 Therapeutic agents

Publications (1)

Publication Number Publication Date
AR044802A1 true AR044802A1 (es) 2005-10-05

Family

ID=27636795

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040102112A AR044802A1 (es) 2003-06-18 2004-06-17 Sales farmaceuticamente aceptables, de derivados de acidos carboxilicos

Country Status (21)

Country Link
US (1) US20060194879A1 (es)
EP (1) EP1638921A1 (es)
JP (1) JP3836498B1 (es)
KR (1) KR20060017646A (es)
CN (1) CN1805922A (es)
AR (1) AR044802A1 (es)
AU (1) AU2004247611A1 (es)
BR (1) BRPI0411455A (es)
CA (1) CA2527608A1 (es)
CO (1) CO5650229A2 (es)
GB (1) GB0314136D0 (es)
IL (1) IL172168A0 (es)
IS (1) IS8232A (es)
MX (1) MXPA05013713A (es)
NO (1) NO20055923L (es)
RU (1) RU2005138369A (es)
SA (1) SA04250170B1 (es)
TW (1) TW200503678A (es)
UY (1) UY28371A1 (es)
WO (1) WO2004110985A1 (es)
ZA (1) ZA200510199B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0104334D0 (sv) * 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
SE0104333D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
GB0314079D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0229931D0 (en) * 2002-12-21 2003-01-29 Astrazeneca Ab Therapeutic agents
MXPA04012686A (es) 2002-06-20 2005-03-23 Astrazeneca Ab Derivados de acido benzoico orto-sustituidos para el tratamiento de la resistencia a la insulina.
WO2007004957A1 (en) * 2005-07-05 2007-01-11 Astrazeneca Ab Novel crystalline form
AR055073A1 (es) * 2005-07-11 2007-08-01 Astrazeneca Ab Agentes terapeuticos
FR2903985B1 (fr) 2006-07-24 2008-09-05 Sanofi Aventis Sa Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
FR2904316B1 (fr) 2006-07-31 2008-09-05 Sanofi Aventis Sa Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique.
PE20081463A1 (es) * 2006-10-20 2008-10-18 Janssen Pharmaceutica Nv Formas salinas de compuestos de benzotienilo sustituido

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL145732A0 (en) * 1999-04-06 2002-07-25 Sankyo Co α-SUBSTITUTED CARBOXYLIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
SE0104334D0 (sv) * 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents

Also Published As

Publication number Publication date
CA2527608A1 (en) 2004-12-23
CN1805922A (zh) 2006-07-19
UY28371A1 (es) 2005-01-31
KR20060017646A (ko) 2006-02-24
SA04250170B1 (ar) 2007-10-29
EP1638921A1 (en) 2006-03-29
JP2006527767A (ja) 2006-12-07
IS8232A (is) 2006-01-13
MXPA05013713A (es) 2006-06-27
IL172168A0 (en) 2009-02-11
GB0314136D0 (en) 2003-07-23
BRPI0411455A (pt) 2006-07-18
US20060194879A1 (en) 2006-08-31
AU2004247611A1 (en) 2004-12-23
ZA200510199B (en) 2006-12-27
WO2004110985A1 (en) 2004-12-23
TW200503678A (en) 2005-02-01
JP3836498B1 (ja) 2006-10-25
CO5650229A2 (es) 2006-06-30
NO20055923L (no) 2006-01-06
RU2005138369A (ru) 2007-07-27

Similar Documents

Publication Publication Date Title
EA200701913A1 (ru) Лечение статином, омега-3 жирными кислотами и их комбинированным продуктом
BR112013027028A2 (pt) preparo de gadobutrol de alta pureza
SG10201909122QA (en) Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
UY27300A1 (es) Nuevos derivados de quinolina
CO5650229A2 (es) Sales farmaceuticamente utiles de derivados de acido carboxilico
UY29065A1 (es) Derivados del ácido alcanoico arilcicloalquil-sustituidos, procedimientos para su preparación y su uso como productos farmacéuticos.
SMT201300095B (it) Uso dell'estere etilico dell'acido eicosapentaenoico per trattare l'ipertrigliceridemia
AR070357A1 (es) Producto para cuidado oral y metodos de uso y manufactura del mismo
CO6341548A2 (es) Nuevos lipidos que contienen azufre para el uso como suplemento alimenticio o como medicamento
CY1108700T1 (el) Συνθεσεις απελευθερωσης φαρμακου εστερα αλφα-υδροξυ οξεος και μεθοδοι χρησης
CR9703A (es) Derivados de pirazolona
UY27646A1 (es) Derivados de quinolina como antagonistas de npt
SG166125A1 (en) New pyrimidine derivatives and their use in therapy as well as the use of pyrimidine derivatives in the manufacture of a medicament for prevention and/or treatment of alzheimeræs disease
AR080491A1 (es) Formulaciones orales y sales lipofilicas de metilnaltrexona
UY32691A (es) Compuestos de 1h-imidazo-[4,5-c]-quinolinona
NI200800227A (es) Acidos 1,3-dioxano carboxilicos
UY31609A1 (es) "(-) ácido 2-[1-(7-metil-2-(morfolin-4-il) 4-oxo-4h-pirido[1,2-a]pirimidin-9-il)etilamino]benzoico enantioméricamente puro, su uso en terapia médica, y una composición farmacéutica que lo comprende-026."
AR069508A1 (es) Derivados de quinolina 057; un proceso para su preparacion; una composicion farmaceutica; la preparacion de esta y el uso del compuesto para preparar un medicamento
RS52867B (en) GLATIRAMER ACETATOM AND RAZAGILIN COMBINED THERAPY FOR MULTIPLE SCLEROSIS
CY1120852T1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει ιβουπροφαινη, τραμαδολη και ενα βασικο αμινοξυ, μεθοδος παρασκευης αυτης και χρηση της ιδιας
ES2531516T3 (es) Uso de escina
AR060568A1 (es) Acidos bifenilcarboxilicos substituidos y sus derivados
AR063538A1 (es) Tratamiento de la enfermedad de parkinson
PE20141539A1 (es) Una nueva composicion terapeutica que contiene apomorfina como principio activo
PE20030277A1 (es) Composicion farmaceutica que comprende 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-cromano y l-dopa

Legal Events

Date Code Title Description
FA Abandonment or withdrawal